Zobrazeno 1 - 2
of 2
pro vyhledávání: '"B. Beñaran"'
Fludarabine Monophosphate in Indolent Non Hodgkin’s Lymphoma (NHL) - Clinical Experience (1995–2006)
Autor:
R. De Bellis, S. Brignoni, A. Sosa, J.E. Novoa, L. Diaz, P. Segura, B. Beñaran, A. Luongo, M. Rivero, J. Segura, N. Iriondo, R. Draper, H. Calvo, A.L. Rojo
Publikováno v:
Blood. 108:4664-4664
Background: fludarabine (F) is licensed for the management of indolent non Hodgkin’s lymphoma in countries such as Canada and Switzerland. Clinical evidence suggests that fludarabine monotherapy is as least as effective, than conventional therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48ba3ba6d8fcb6f39bdb65a0b4ed37ed
https://doi.org/10.1182/blood.v108.11.4664.4664
https://doi.org/10.1182/blood.v108.11.4664.4664
Autor:
H. Calvo, L. Diaz, S. Brignoni, A. Cabrera, N. Iriondo, R. Draper, M. Rivero, J.E. Novoa, A.L. Rojo, M. Pebet, R. De Bellis, B. Beñaran, A. Luongo
Publikováno v:
Blood. 108:4970-4970
Background: fludarabine (F) has become the standard first line therapy for chronic lymphocytic leukemia (CLL) in younger patients. Treatment of early stage patients with chlorambucil without risk stratification has not been shown to prolong survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfebbafd3f702f297c4b4d3edc676499
https://doi.org/10.1182/blood.v108.11.4970.4970
https://doi.org/10.1182/blood.v108.11.4970.4970